

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/apm-22-1130	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	In particular, we shared the changes in defecation frequency for one week before and after nardimedine administration and found that nardimedine has improved clinical efficacy and is safe when used as a treatment for opioid-induced constipation.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since survival data may be updated over time.
7	To whom will you share the data?	Physicians with insight into clinical oncology and palliative medicine who have the opportunity to prescribe opioids.
8	For what type of analysis or purpose?	For analysis to evaluate the clinical efficacy and safety of naldemedine in opioid-induced constipation.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: m06701014@gunma-u.ac.jp

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.
----	-------------------------	--